Drug Profile
Recombinant human insulin - Reliance GeneMedix
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator GeneMedix Plc
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2015 Discontinued - Clinical-Phase-Unknown for Type-1 diabetes mellitus in United Kingdom (Parenteral) before May 2015
- 28 May 2015 Discontinued - Clinical-Phase-Unknown for Type-2 diabetes mellitus in United Kingdom (Parenteral) before May 2015